Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05930028
Other study ID # BR-FAEC-CT-301
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date July 13, 2023
Est. completion date June 2024

Study information

Verified date December 2023
Source Boryung Pharmaceutical Co., Ltd
Contact shinyoung Oh
Phone +82-2-708-8000
Email syoh@boryung.co.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this clinical study is to evaluate the efficacy and safety by comparing BR1017A+BR1017B treatment group to BR1017A treatment group and BR1017B treatment group respectively at Week 8 in essential hypertension patients with primary hypercholesterolemia


Recruitment information / eligibility

Status Recruiting
Enrollment 156
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility <Inclusion Criteria> Screening - Patients with essential hypertension and primary hypercholesterolemia - If patients are being treated with antihypertensive/antihyperlipidemic drugs at screening (V1), they should be determined to be medically reasonable by investigator about discontinuing existing antihypertensive/ antihyperlipidemic drugs during the clinical trial - Patients who have an fasting triglyceride (TG) < 400 mg/dL and LDL-C = 250 mg/dL at Screening (V1) - Voluntarily provided a written consent to participate in this clinical study - Able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion Randomization - Patients who meet the following criteria of blood pressure measured in selected reference arm before randomization at baseline(V3) - 140 mmHg = MSSBP < 180 mmHg - MSDBP < 110 mmHg - Patients who meet the criteria of fasting serum lipid levels and risk factors at pre-baseline (V2) after undergoing the therapeutic lifestyle change (TLC) - Patients who have an fasting triglyceride (TG) < 400 mg/dL and LDL-C = 250 mg/dL after undergoing the therapeutic lifestyle change (TLC) for at least 4 weeks before pre-baseline (V2) <Exclusion Criteria> - Patients with blood pressure results showing MSSBP = 180 mmHg or MSDBP = 110 mmHg in the selected reference arm at screening(V1) or Baseline(V3) - Patients with a difference of MSSBP = 20 mmHg and MSDBP = 10 mmHg in blood pressure measured three times on both arms at screening(V1) - Patients with past history and comorbidities at screening(V1) under the following criteria: - Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, Cushing's syndrome, pheochromocytoma and polycystic kidney disease, etc.) - Patients with secondary hyperlipidemia: Secondary hyperlipidemia is not limited to the following diseases; (e.g., Chronic renal failure, nephrotic syndrome, obstructive liver disease, hypothyroidism, dysproteinemia, etc.) - Patients with orthostatic hypotension accompanied by symptoms

Study Design


Intervention

Drug:
Fimasartan
Subjects take the investigational products once a day for 8 weeks.
Ezetimibe/Atorvastatin
Subjects take the investigational products once a day for 8 weeks.
Fimasartan Placebo
Subjects take the investigational products once a day for 8 weeks.
Ezetimibe/Atorvastatin Placebo
Subjects take the investigational products once a day for 8 weeks.

Locations

Country Name City State
Korea, Republic of Severance Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Boryung Pharmaceutical Co., Ltd

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean sitting systolic blood pressure The change of mean sitting systolic blood pressure from baseline in BR1017A+BR1017B at Week 8 compared to BR1017B 8weeks from Baseline Visit
Primary LDL-C The percent of change in LDL-C from baseline in BR1017A+BR1017B at Week 8 compared to BR1017A 8weeks from Baseline Visit
Secondary LDL-C The percent of change in LDL-C from baseline in BR1017A+BR1017B at Week 8 compared to BR1017B 8weeks from Baseline Visit
Secondary Mean sitting systolic blood pressure The change of mean sitting systolic blood pressure from baseline in BR1017A+BR1017B at Week 8 compared to BR1017A 8weeks from Baseline Visit
See also
  Status Clinical Trial Phase
Recruiting NCT03708601 - Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
Not yet recruiting NCT05503953 - Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS Phase 3
Recruiting NCT05526703 - Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy Phase 3
Completed NCT06395194 - Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension Phase 3
Not yet recruiting NCT06418074 - Effects of Exogenous Ketosis on Renal Function, Renal Perfusion, and Sodium Excretory Capacity N/A
Completed NCT02890173 - Study of CS-3150 in Patients With Essential Hypertension Phase 3
Completed NCT02944734 - Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension Phase 2
Withdrawn NCT02096939 - Microvascular Function in Primary Aldosteronism N/A
Recruiting NCT01956786 - Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine Phase 2/Phase 3
Completed NCT02553512 - Helius in Hypertension-I: The UK Hypertension Registry N/A
Completed NCT01198249 - Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension Phase 1
Completed NCT01001572 - Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension Phase 3
Recruiting NCT00380289 - Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension N/A
Completed NCT00139698 - Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension Phase 3
Completed NCT00288184 - Uric Acid in Essential Hypertension in Children Phase 2
Completed NCT01289886 - Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects Phase 1
Not yet recruiting NCT06041529 - Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension Phase 4
Completed NCT04470830 - A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
Completed NCT00758524 - A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension Phase 2
Recruiting NCT05109013 - Juvenile Essential Arterial Hypertension and Vascular Function